513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Xenia Hotels & Resorts reported a third-quarter net loss of $7.1 million, or $0.07 per share, narrowed from $8.5 million a year earlier, while total revenues rose to $236.8 million from $232.0 million. Adjusted EBITDAre fell 4.4% to $44.3 million, and the company lowered its full-year 2024 outlook for net income, Adjusted EBITDAre and Adjusted FFO per diluted share, citing renovation disruption, hurricanes and softer leisure demand.
Q3 2024 Adjusted EBITDAre was $44.3 million, down 4.4%; Adjusted FFO per diluted share was $0.25, down 3.8%
Full-year 2024 Adjusted EBITDAre guidance is $234 million to $242 million, a reduction of $9 million to $13 million from prior guidance
Full-year 2024 Adjusted FFO per diluted share guidance is $1.54 to $1.62, down $0.08 to $0.12 from prior guidance
Hurricanes are estimated to reduce Hotel EBITDA by approximately $2 million over the third and fourth quarters
TKO reported third quarter 2024 revenue of $681.2 million, up 52%, and net income of $57.7 million, up from $22.0 million a year earlier, driven mainly by WWE, which was consolidated only from September 12, 2023. The company now expects full-year 2024 revenue and Adjusted EBITDA at the upper end of its August ranges, and UFC segment revenue and Adjusted EBITDA both declined in the quarter.
Q3 2024 revenue $681.2 million, up $232.1 million; WWE revenue $326.3 million, UFC revenue $354.9 million, down 11%
Q3 2024 Adjusted EBITDA $310.0 million, up 29%; net income attributable to TKO Group Holdings was $23.1 million, or $0.29 basic EPS
Full-year 2024 revenue expected at upper end of $2.670 billion to $2.745 billion; Adjusted EBITDA at upper end of $1.220 billion to $1.240 billion
Cash and cash equivalents $457.4 million and gross debt $2.736 billion as of September 30, 2024
Tandem Diabetes Care reported third quarter 2024 GAAP sales of $244.0 million, up 31% from a year earlier, and raised its 2024 non-GAAP sales guidance to $903 million to $910 million. The net loss narrowed to $23.3 million from $33.0 million, which supports the company's revenue growth and improving loss trend for shareholders.
Q3 2024 GAAP sales were $244.0 million, up 31% from $185.6 million; non-GAAP sales were $242.9 million, up 25%.
GAAP net loss was $23.3 million, or $0.35 per share, compared with $33.0 million, or $0.51 per share, a year earlier.
Full-year 2024 non-GAAP sales guidance is now approximately $903 million to $910 million, with U.S. sales of $645 million to $650 million.
Non-GAAP gross margin guidance of about 51% and Adjusted EBITDA margin guidance of breakeven were reaffirmed.
Schneider National reported third-quarter 2024 operating revenues of $1,315.7 million, down from $1,352.0 million a year earlier, and diluted earnings per share of $0.17 versus $0.20. The company lowered its full-year 2024 adjusted diluted earnings per share guidance to $0.66-$0.72 from $0.80-$0.90, citing shifted expectations for the timing of a freight market recovery. For shareholders, the filing shows lower earnings and a reduced profit outlook for the year.
Q3 2024 operating revenues were $1,315.7 million, compared with $1,352.0 million in Q3 2023.
Q3 2024 income from operations was $43.1 million, down 8% from $46.7 million; diluted EPS was $0.17 versus $0.20.
Full-year 2024 adjusted diluted EPS guidance was cut to $0.66-$0.72 from $0.80-$0.90.
Net capital expenditures guidance was updated to approximately $330.0 million, within the prior range of $300.0-$350.0 million.
Charles River reported third-quarter 2024 revenue of $1.01 billion, down 1.6% from a year earlier, with GAAP diluted EPS of $1.33, down 21.3%, and non-GAAP diluted EPS of $2.59, down 4.8%. The company raised its 2024 non-GAAP EPS guidance to $10.10-$10.30 from $9.90-$10.20 but cut its GAAP EPS guidance to $5.30-$5.50 from $5.65-$5.95, citing higher restructuring charges.
Q3 revenue $1.01 billion vs. $1.03 billion in Q3 2023; organic revenue declined 2.7%
GAAP diluted EPS $1.33 vs. $1.69; non-GAAP diluted EPS $2.59 vs. $2.72
2024 non-GAAP EPS guidance raised to $10.10-$10.30; GAAP EPS guidance cut to $5.30-$5.50
Board approved a $1.0 billion buyback on August 2, 2024; $899.3 million remained as of September 28, 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.